About Dihydropyrimidinase
Dihydropyrimidinase (DPYS) is a protein
from Homo sapiens identified by UniProt accession
Q14117, 519 residues long.
MolForge cross-references it against 0 known binders and
76 disease associations.
Target properties
| Protein name | Dihydropyrimidinase |
| UniProt accession | Q14117 |
| Gene | DPYS |
| Organism | Homo sapiens |
| Length | 519 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (76)
Diseases linked to this target (Open Targets).
- dihydropyrimidinuria · score 0.77
- genetic disorder · score 0.41
- metabolite measurement · score 0.30
- 3-ureidopropionate measurement · score 0.30
- salivary metabolite measurement · score 0.30
- Paralytic ileus · score 0.24
- cutaneous melanoma · score 0.22
- blood protein measurement · score 0.19
- osteitis deformans · score 0.18
- irritability measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14117-F1 | alphafold | PREDICTED | 95.82 | — |
Amino-acid sequence (519 residues)
MAAPSRLLIR GGRVVNDDFS EVADVLVEDG VVRALGHDLL PPGGAPAGLR VLDAAGKLVL PGGIDTHTHM QFPFMGSRSI DDFHQGTKAA LSGGTTMIID FAIPQKGGSL IEAFETWRSW ADPKVCCDYS LHVAVTWWSD QVKEEMKILV QDKGVNSFKM FMAYKDLYMV TDLELYEAFS RCKEIGAIAQ VHAENGDLIA EGAKKMLALG ITGPEGHELC RPEAVEAEAT LRAITIASAV NCPLYIVHVM SKSAAKVIAD ARRDGKVVYG EPIAASLGTD GTHYWNKEWH HAAHHVMGPP LRPDPSTPDF LMNLLANDDL TTTGTDNCTF NTCQKALGKD DFTKIPNGVN GVEDRMSVIW EKGVHSGKMD ENRFVAVTST NAAKIFNLYP RKGRIAVGSD ADIVIWDPKG TRTISAKTHH QAVNFNIFEG MVCHGVPLVT ISRGKVVYEA GVFSVTAGDG KFIPRKPFAE YIYKRIKQRD RTCTPTPVER APYKGEVATL KSRVTKEDAT AGTRKQAHP
Explore Dihydropyrimidinase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets